The 12 Percent Tissue Company

KP Tissue is a publicly traded company whose entire business is owning 12.1% of something else.

That something else is Kruger Products, Canada's largest tissue manufacturer by dollar and volume market share - the operator behind Cashmere, Scotties, SpongeTowels, and the whole commercial dispensing business. The remaining 87.9% of Kruger is held by the Kruger majority, a private owner that sets strategy, approves capex, and decides where the cash goes. KP Tissue's public shareholders, who traded the stock around CA$11.40 this week, get the dividend and the quarterly earnings release. The rest is someone else's problem.

This is not the weirdest ownership structure in finance, but it is the sort of plumbing detail that explains why the quarterly narrative sounds the way it does - and why investors in KP Tissue are, in effect, buying a very small piece of a very large machine controlled by someone who doesn't have to answer to them.

The first-quarter 2026 results read like a cost-management victory lap. Revenue was essentially flat at CAD 544.6 million (down 0.3% year-over-year), while adjusted EBITDA - earnings before interest, taxes, depreciation, and amortization, a rough proxy for cash earnings - rose 14.6% to CAD 86.9 million. The margin hit 16%, up from 14% a year earlier.

The drivers were commodity prices and logistics, not pricing power. Pulp prices fell - specifically NBSK, the northern bleached softwood kraft grade used in premium tissue - and warehousing costs came down. CEO Dino Bianco said the company rejected "aggressive or premature" supplier cost increases. CFO Michael Keays confirmed no new price increases had been announced. The margin expansion came from the bottom up, not the top down.

That matters because the cost tailwind looks temporary. Industry analysts expect both NBSK and BEK (bleached eucalyptus kraft, used in paper towels and thicker products) to rise in 2026, with BEK moving higher and faster. Bianco himself acknowledged that Middle East geopolitical risk could push fuel and freight costs up in the second half. The Q1 beat was a function of where pulp happened to be at that moment, not a structural improvement in the business model.

The segment splits tell a slightly more interesting story. The Consumer segment - bathroom tissue, facial tissue, paper towels sold at retail - saw revenue decline 0.8% year-over-year, but EBITDA jumped to CAD 83.9 million from CAD 76.1 million, pushing margins to 18.2%, up two percentage points. That's the bulk of the business doing its job: stable volume, input cost relief, margin expansion.

Away-From-Home - the commercial and institutional dispensing business - is where things moved more dramatically. Revenue rose 2.5% to CAD 82.9 million, and adjusted EBITDA more than doubled to CAD 6.3 million from CAD 2.8 million a year earlier. The margin hit 7.6%. Keays attributed part of the improvement to insourcing paper supply, meaning Kruger is making its own commercial tissue rather than buying it. Bianco said the U.S. market was the main growth driver, which tracks with the Memphis facility ramp-up that began in early April.

The Away-From-Home improvement is real, but the base was tiny. Doubling EBITDA from CAD 2.8 million sounds impressive until you notice it's still less than 1% of the company's total revenue. It's encouraging, but it doesn't carry the thesis.

Here's where the structure starts to matter more than the quarterly numbers.

KP Tissue pays a dividend that yields about 6.3%. For a publicly traded tissue company, that's high but not unheard of - consumer staples with predictable cash flows often sit in that range. The payout ratio (the fraction of earnings paid out as dividends) appears sustainable at current levels, around 71% to 85% depending on which earnings measure you use.

But the question isn't whether the dividend is affordable. The question is what the public shareholder actually owns, and what they can influence.

When you buy KP Tissue stock, you are buying a fraction of a company that holds a fraction of the operating business. Kruger Products generates the cash. The Kruger majority controls Kruger Products. KP Tissue takes its slice of cash flow and passes some of it to shareholders as dividends. The leverage ratio fell to 2.9 times net debt to EBITDA from 3.1 times in the prior quarter - which is good for credit quality, but that leverage sits at the operating company level, where the majority owner calls the shots.

The upcoming capex program - CAD 100-120 million for full-year 2026, plus the planned western U.S. Through-Air-Dried tissue plant with an expected late-2028 startup - represents real investment in growth. TAD tissue is the premium segment: thicker, softer, higher-margin, competing in the ultra-premium space. Bianco said the company is finalizing incentives, permitting, and financing for the project, with an official announcement expected before mid-2026.

But who decides whether that project gets built, how much it costs, and whether it earns its keep? The Kruger majority. KP Tissue's public shareholders get the earnings release.

This isn't inherently a problem. Many minority public interests in operating businesses work fine when the majority owner has aligned incentives and the dividend policy is credible. But it does mean that strategic decisions - pricing, capacity, competitive response - are made at arm's length.

The competitive landscape reinforces why that structure is worth keeping in mind. Georgia-Pacific announced on May 12 that it's expanding premium tissue capacity. The industry is adding capacity while utilization rates sit in the "mid-low 90s," Bianco's description. That's tight, but new supply coming online always carries the risk of short-term oversupply, even if long-term demand supports it.

When industry utilization cracks and margins get pressured, the company that controls the cost structure and pricing discipline wins. KP Tificio doesn't control either one.

So what's the machine, really?

KP Tissue is a yield vehicle for a tissue operation. You get the dividend, you get the quarterly updates, you get the benefit of margin expansion when pulp prices cooperate and the headache of margin compression when they don't. The 6.3% yield is the price the market assigns to that stream - which is, at its core, a claim on a fraction of Kruger Products' cash generation.

The Q1 results show the mechanism working: input cost relief flowed through to margins, the balance sheet ticked higher (CAD 205.9 million in cash, down CAD 16.1 million in debt), and management expects Q2 EBITDA to be roughly in line. That's a healthy quarter for a business that sells toilet paper and paper towels - products nobody buys less of in a recession.

The structural implication is simpler. If you believe the tissue business's cash generation is durable and the dividend is safe, the 12% stake is a convenient wrapper. If you believe strategic execution matters most - pricing power,